Skip to main content

Cerebral correlates of hyponatremia

Neurocritical Care volume 6, pages 72–78 (2007)Cite this article

Abstract

Hyponatremia, defined as a serum sodium concentration ([Na+]) less than 135 mEq/L, is commonly caused by elevated levels of the hormone arginine vasopressin (AVP), which causes water retention. The principal organ affected by disease-related morbidity is the brain. The neurologic complications associated with hyponatremia are attributable to cerebral edema and increased intracranial pressure, caused by the osmotically driven movement of water from the extracellular compartment into brain cells. Although neurologic symptoms induced by hyponatremia are limited by an adaptive brain mechanism known as “regulatory volume decrease,” an overly rapid correction of serum [Na+] before the reversal of this adaptive response can also produce neurologic damage. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) is a frequent cause of hyponatremia related to central nervous system disorders, neurosurgery, or the use of psychoactive drugs. Fluid restriction is the standard of care for patients with SIADH who are asymptomatic or who have only mild symptoms but patients with severe or symptomatic hyponatremia require more aggressive therapy. Infusion of hypertonic saline is the usual approach to the treatment of symptomatic hyponatremia, but patients require frequent monitoring. Pharmacologic agents such as demeclocycline and lithium may be effective in some patients but are associated with undesirable adverse events. The AVP-receptor antagonists are a new therapeutic class for the treatment of hyponatremia. The first agent in this class approved for the treatment of euvolemic hyponatremia in hospitalized patients is conivaptan. Two other agents, tolvaptan and lixivaptan, are being evaluated in patients with euvolemic and hypervolemic hyponatremia. The AVP-receptor antagonists block the effects of elevated AVP and promote aquaresis, the electrolytesparing excretion of water, resulting in the correction of serum [Na+]. These agents may also have intrinsic neuroprotective effects.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Moritz ML, Ayus JC. The pathophysiology and treatment of hyponatraemic encephalopathy: an update. Nephrol Dial Transplant 2003;18:2486–2491.

    Article  PubMed  Google Scholar 

  2. Diringer MN. Management of sodium abnormalities in patients with CNS disease. Clin Neuropharmacol 1992;15:427–447.

    Article  CAS  PubMed  Google Scholar 

  3. Pasantes-Morales H, Franco R, Ordaz B, Ochoa LD. Mechanisms counteracting swelling in brain cells during hyponatremia. Arch Med Res 2002;33:237–244.

    Article  CAS  PubMed  Google Scholar 

  4. Flear CT, Gill GV, Burn J. Hyponatremia: mechanisms and management. Lancet 1981;2:26–31.

    Article  CAS  PubMed  Google Scholar 

  5. Hawkins RC. Age and gender as risk factors for hyponatremia and hypernatremia. Clin Chim Acta 2003;337:169–172.

    Article  CAS  PubMed  Google Scholar 

  6. Fraser CL, Arieff AI. Epidemiology, pathophysiology, and management of hyponatremic encephalopathy. Am J Med 1997;102:67–77.

    Article  CAS  PubMed  Google Scholar 

  7. Rabinstein AA, Wijdicks EFM. Hyponatremia in critically ill neurological patients. Neurologist 2003;9:290–300.

    Article  PubMed  Google Scholar 

  8. Albanese A, Hindmarsh P, Stanhope R. Management of hyponatremia in patients with acute cerebral insults. Arch Dis Child 2001;85:246–251.

    Article  CAS  PubMed  Google Scholar 

  9. Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med 2000;342:1581–1589.

    Article  PubMed  Google Scholar 

  10. Siegel AJ, Baldessarini RJ, Klepser MB, McDonald JC. Primary and drug-induced disorders of water homeostasis in psychiatric patients: principles of diagnosis and management. Harv Rev Psychiatry 1998;6:190–200.

    Article  CAS  PubMed  Google Scholar 

  11. Riggs AT, Dysken MW, Kim SW, Opsahl JA. A review of disorders of water homeostasis in psychiatric patients. Psychosomatics 1991;32:133–148.

    CAS  PubMed  Google Scholar 

  12. Palmer BF, Gates JR, Lader M. Causes and management of hyponatremia. Ann Pharmacother 2003;37:1694–1702.

    Article  PubMed  Google Scholar 

  13. Gullans SR, Verbalis JG. Control of brain volume during hyperosmolar and hypoosmolar conditions. Annu Rev Med 1993; 44:289–301.

    Article  CAS  PubMed  Google Scholar 

  14. Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 2006;119:711–718.

    Article  CAS  Google Scholar 

  15. Ayus JC, Wheeler JM, Arieff AI. Postoperative hyponatremic encephalopathy in menstruant women. JAMA 1992;117:891–897.

    CAS  Google Scholar 

  16. Tierney WM, Martin DK, Greenlee MC, Zerbe RL, McDonald CJ. The prognosis of hyponatremia at hospital admission. J Gen Intern Med 1986;1:380–385.

    Article  CAS  PubMed  Google Scholar 

  17. Anderson RJ, Chung HM, Kluge R, Schrier RW. Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med 1985;102:164–168.

    CAS  PubMed  Google Scholar 

  18. Lester MC, Nelson PB. Neurological aspects of vasopressin release and the syndrome of inappropriate secrection of antidiuretic hormone. Neurosurg 1981;8:735–740.

    Article  CAS  Google Scholar 

  19. Born JD, Hans P, Smitz S, Legros JJ, Kay S. Syndrome of inappropriate secretion of antidiuretic hormone after severe head injury. Surg Neurol 1985;23:383–387.

    Article  CAS  PubMed  Google Scholar 

  20. Casulari LA, Costa KN, Albuquerque RCR, Naves LA, Suzuki K, Domingues L. Differential diagnosis and treatment of hyponatremia following pituitary surgery. J Neurosurg Sci 2003;47:11–18.

    Google Scholar 

  21. Palmer BF. Hyponatremia in patients with central nervous system disease: SIADH versus CSW. Trends Endocrinol Metab 2003;14:182–187.

    Article  CAS  PubMed  Google Scholar 

  22. Dooling E, Winkelman C. Hyponatremia in the patient with subarachnoid hemorrhage. J Neurosci Nurs 2004;36:130–135.

    Article  PubMed  Google Scholar 

  23. Harrigan MR. Cerebral salt wasting syndrome. Crit Care Clin 2001;17:125–138.

    Article  CAS  PubMed  Google Scholar 

  24. Martin RJ. Central pontine and extrapontine myelinolysis: the osmotic demyelination syndromes. J Neurol Neurosurg Psychiatry 2004;75(suppl III):iii22-iii28.

    Article  PubMed  Google Scholar 

  25. Mulloy AL, Caruana RJ. Hyponatremic emergencies. Med Clin North Am 1995;79:155–168.

    CAS  PubMed  Google Scholar 

  26. Massieu L, Montiel T, Robles G, Quesada O. Brain amino acids during hyponatremia in vivo: Clinical observations and experimental studies. Neurochem Res 2004;29:73–81.

    Article  CAS  PubMed  Google Scholar 

  27. Decaux G. Treatment of symptomatic hyponatremia. Am J Med Sci 2003;326:25–30.

    Article  PubMed  Google Scholar 

  28. Musana AK, Yale SH. Central pontine myelinolysis: case series and review. WMJ 2005;104:56–60.

    PubMed  Google Scholar 

  29. Menger H, Jorg J. Outcome of central pontine and extrapontine myelinolysis. J Neurol 1999;246:700–705.

    Article  CAS  PubMed  Google Scholar 

  30. Stern RH. Severe symptomatic hyponatremia: treatment and outcome. Ann Intern Med 1987;107:656–664.

    Google Scholar 

  31. Sterns RH, Cappuccio JD, Silver S, Cohen EP. Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. J Am Soc Nephrol 1994;4:1522–1530.

    CAS  PubMed  Google Scholar 

  32. Ayus JC, Krothapalli RK, Arieff AI. Treatment of symptomatic hyponatremia and its relation to brain damage. A prospective study. N Engl J Med 1987;317:1190–1195.

    CAS  PubMed  Article  Google Scholar 

  33. Oh MS, Kim HJ, Carroll JH, et al. Recommendations for treatment of symptomatic hyponatremia. Nephron 1995;70:143–150.

    Article  CAS  PubMed  Google Scholar 

  34. Gross P, Reimann D, Henschkowski J, Damian M. Treatment of severe hyponatremia: conventional and novel aspects. J Am Soc Nephrol 2001;12:S10-S14.

    CAS  PubMed  Google Scholar 

  35. Verbalis JG. Vasopressin V2 receptor antagonists. J Mol Endocrinol 2002;29:1–9.

    Article  CAS  PubMed  Google Scholar 

  36. Trandafir CC, Nishihashi T, Wang A, Murakami S, Ji X, Kurahashi K. Participation of vasopressin in the development of cerebral vasospasm in a rat model of subarachnoid haemorrhage. Clin Exp Pharmacol Physiol 2004;31:261–266.

    Article  CAS  PubMed  Google Scholar 

  37. Shuaib A, Wang CX, Yang T, Noor R. Effects of nonpeptide V1 vasopressin receptor antagonist SR-49059 on infarction volume and recovery of function in a focal embolic stroke model. Stroke 2002;33:3033–3037.

    Article  CAS  PubMed  Google Scholar 

  38. Vakili A, Kataoka H, Plesnila N. Role of arginine vasopressin V1 and V2 receptors for brain damage after transient focal cerebral ischemia. J Cereb Blood Flow Metab 2005;25:1012–1019.

    Article  CAS  PubMed  Google Scholar 

  39. Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure. Results from a double-blind, randomized trial. Circulation 2003;107:2690–2696.

    Article  CAS  PubMed  Google Scholar 

  40. Gheorghiade M, Gattis WA, O’Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure. A randomized controlled trial. JAMA 2004;291:1963–1971.

    Article  CAS  PubMed  Google Scholar 

  41. Wong F, Blei AT, Blendis LM, Thuluvath PJ, for the North American VPA-985 Study Group. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 2003;37:182–191.

    Article  CAS  PubMed  Google Scholar 

  42. Verbalis JG, Bisaha JG, Smith N. Novel vasopressin V1A and V2 antagonist conivaptan increases serum sodium concentration and effective water clearance in hyponatremia [abstract]. J. Am Soc Nephrol 2004;15:356A. Abstract SA-P0254.

    Google Scholar 

  43. Ghali JK, Koren MJ, Taylor JR, et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 2006;91:2145–2152.

    Article  CAS  PubMed  Google Scholar 

  44. Gross P, Bisaha JG, Smith N. Conivaptan, a novel V1A and V2 antagonist, increased serum sodium and effective water clearance in patients with euvolemic or hypervolemic hyponatremia [abstract]. J Am Soc Nephrol 2004;15:355A. Abstract SA-P0243.

    Article  CAS  Google Scholar 

  45. Verbalis JG, Ghali JK, Gross P, Long WA, Smith N. Efficacy and safety of the vasopressin antagonist conivaptan in patients with euvolemic hyponatremia evaluated in a phase III clinical trial. J Clin Oncol 2006;24(suppl 18S:480s.

    Google Scholar 

  46. Bichet DG, Madore F, Cusson J, et al. Pharmacotherapy for hyponatremia in SIADH: effects of a new orally administered dual V1A/V2 vasopressin antagonist YM087. J Am Soc Nephrol 1999;10: A0613.

    Google Scholar 

  47. Abraham W, Koren M, Bichet DG, et al. Treatment of hyponatraemia in patients with SIADH or CHF with intravenous conivaptan (YM087), a new combined vasopressin V1A/V2 receptor antagonist. Eur Heart J 2000;21 (abstr suppl):345.

    Google Scholar 

  48. Gross P, Palm C. The treatment of hyponatremia using vasopressin antagonists. Exp Physiol 2000;85S:253S-257S.

    Article  Google Scholar 

Download references

Author information

Affiliations

  1. University of Virginia, Department of Neurology, Box 800394, 22908, Charlottesville, VA

    Barnett R. Nathan

Authors
  1. Barnett R. Nathan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Barnett R. Nathan.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Nathan, B.R. Cerebral correlates of hyponatremia. Neurocrit Care 6, 72–78 (2007). https://doi.org/10.1385/NCC:6:1:72

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1385/NCC:6:1:72

Key Words

  • Hyponatremia
  • SIADH
  • regulatory volume decrease
  • osmotic demyelination syndromes
  • AVP-receptor antagonists